U.S. Supreme Court Case on Medication Abortion and Its Impact on Patient Access in Wichita
A case before the U.S. Supreme Court could drastically limit access to medication abortions, now the most common form of abortion in the United States. This legal challenge could roll back rules about drugs used in medication abortions, eliminating virtual clinics and mailed prescriptions, at a time when most U.S. abortions rely on pharmaceuticals.
Increased Patient Flow to Wichita
Such a decision could increase the already fast-growing flow of patients to Wichita trying to escape abortion bans that have swept through the region since the high court overturned Roe v. Wade in June 2022. Dr. Kelly Pfeifer said she is preparing for a surge of even more patients if the justices change rules around the abortion pill mifepristone. As a family medicine doctor, she noted that her 15-month-old Wichita clinic, Aria Medical Clinic, saw 3,100 patients in 2023 — nearly all from states where abortion is no longer legally available.
Aria, which only offers medication abortions, set up shop in Kansas soon after the high court gave states the authority to impose bans in 2022. This facility expands abortion access by focusing on medication abortions, which rely on a regimen of two drugs, rather than surgery, to end early-stage pregnancies. Medication abortions are less expensive and are often available through telehealth appointments, although Aria only sees patients in person.
Understanding Medication Abortion
Medication abortion is also known as abortion with pills or medical abortion. It is endorsed by several organizations, including the American College of Obstetricians & Gynecologists and the American Medical Association. Regarding its regulated use, the Food and Drug Administration has approved medication abortion for up to 10 weeks of pregnancy and the World Health Organization authorizes its use for up to 12 weeks.
Current Data and Statistics
The following table summarizes key data points regarding medication abortion and clinic operations mentioned in the research:
| Category | Details |
|---|---|
| Aria Medical Clinic Patients (2023) | 3,100 patients |
| FDA Approval Limit | Up to 10 weeks of pregnancy |
| WHO Authorization Limit | Up to 12 weeks of pregnancy |
| Prevalence of Method | 51% of all abortions |
The Legal Landscape and Supreme Court Rulings
On June 13, the Supreme Court justices in a unanimous decision preserved access to mifepristone, a medication that’s used for the safe termination of early pregnancy, writing that “federal courts are the wrong forum for addressing the plaintiffs’ concerns about FDA’s actions.” The legal future of mifepristone had hung in the balance for several months prior to this.
In August 2023, the 5th U.S. Circuit Court of Appeals ruled that mifepristone should not be prescribed past the seventh week of pregnancy, prescribed via telemedicine, or shipped to patients through the mail. While the Supreme Court eventually preserved access, the case highlights how measures that aim to ban, restrict, or expand abortion rights continue to impact the medical landscape. For journalists and the public, it is important to have a good understanding of medication abortion so that they can better inform their audiences with scientific evidence.